Iterum Therapeutics
About Iterum Therapeutics
Iterum Therapeutics Limited: Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.We are pursuing a balanced development strategy with multiple opportunities intended to treat the organisms responsible for many serious infections, which the Centers for Disease Control (CDC) has determined to be inadequately addressed by current therapies1.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Corey N. Fishman
CSO: Michael Dunne, MD
CFO: Judith M. Matthews
VP, Operations: Benjamin M. PE
VP, Development: Sailaja Puttagunta, MD
VP, Business Development & Supply Chain: John J. White
CAREER:
Please click here for Iterum Therapeutics' job opportunities.
89 articles with Iterum Therapeutics
-
Iterum Therapeutics Reports First Quarter 2022 Financial Results
5/13/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2022.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Iterum Therapeutics Provides Regulatory Update - May 11, 2022
5/11/2022
Iterum Therapeutics plc announced it met with the US Food and Drug Administration on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company’s new drug application for oral sulopenem etzadroxil-probenecid for the treatment of uncomplicated urinary tract infections.
-
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
4/25/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), today announced two poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.
-
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/28/2022
Iterum Therapeutics plc today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
3/21/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Monday, March 28, 2022
-
Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
3/10/2022
Iterum Therapeutics plc announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550.
-
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 08, 2022
2/8/2022
Iterum Therapeutics plc announced that it has granted a non-statutory share option to purchase an aggregate of 50,000 ordinary shares of the Company as an inducement to a newly hired employee.
-
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 14, 2021
12/14/2021
Iterum Therapeutics plc announced that it has granted a non-statutory share option to purchase an aggregate of 1,800,000 ordinary shares of Iterum Therapeutics and 500,000 restricted share units to Sailija Puttagunta, M.D., Iterum Therapeutics’ newly appointed Chief Medical Officer.
-
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer
12/13/2021
Iterum Therapeutics plc today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical evelopment and regulatory initiatives for Iterum.
-
Iterum Therapeutics will head back into the clinic to meet regulatory requirements to refile a New Drug Application for oral sulopenem.
-
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
11/12/2021
Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the third quarter ended September 30, 2021.
-
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
11/5/2021
Iterum Therapeutics plc today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Friday, November 12, 2021.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Iterum Therapeutics to Present Data at IDWeek 2021
9/28/2021
Iterum Therapeutics plc today announced a data presentation at the Infectious Disease Society of America (IDSA) IDWeek TM 2021, taking place virtually from September 29 – October 3, 2021.
-
Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem
9/28/2021
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem).
-
Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference.
-
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
8/13/2021
Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the second quarter ended June 30, 2021.
-
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on August 13, 2021
8/6/2021
Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Friday, August 13, 2021.
-
The U.S. Food and Drug Administration (FDA) had several PDUFA dates on their calendar for the last week of July, but in two cases, there were problems with the submissions ahead of time. Here’s a look.